WHO Classification of Tumours: evolution of a global resource in the molecular era.

COI Statement

WAC has received support for travel to attend meetings from AstraZeneca. BR has received support for travel and accommodation to attend meetings from International Agency for Research on Cancer (IARC), Union for International Cancer Control, and American Joint Committee on Cancer. AR has recevied payment for participation at advisory board meetings for Amgen, AstraZeneca, BMS, EliLilly, Gilead, Merck, MSD, Roche, and Sanofi; as invited speaker for Amgen, Bayer, and BMS; and has received travel support from EliLilly, Gilead, Sanofi–Gilead, and Sanofi. All other authors declare no competing interests. The content of this Comment represents the personal views of the authors and does not represent the views of the authors’ employers and associated institutions. Where authors are identified as personnel of IARC or WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of IARC or WHO. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Copyright © 2025 World Health Organization. Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.